Business Wire

AI EdgeLabs Adds Advanced Risk and Compliance Center with Linux Audit Capabilities to Its AI Runtime Platform

13.1.2026 10:00:00 CET | Business Wire | Press Release

Share

AI EdgeLabs, the pioneer in autonomous AI runtime platform, today announced the launch of Compliance Center and Linux Audit. Purpose-built for organizations facing NIS2, CRA, and global critical-infrastructure mandates, the new capabilities replace manual reporting and scan-based compliance with continuous visibility, automated control coverage, and real-time posture insights.

Key capabilities include:

  • A single Risk Score representing their current posture
  • Real-time compliance visibility for CRA and NIS2
  • Prioritized assets based on impact and criticality
  • Extended support for firmware, custom OS, and RTOS
  • Linux audit and configuration hardening insights
  • Automated, framework-specific checklists
  • Incident Reporting and Automated Response

“As NIS2 and the Cyber Resilience Act come into force, companies need continuous proof of compliance, not manual mapping or siloed visibility,” said Inna Ushakova, CEO of AI EdgeLabs. “This release provides real-time compliance posture, instant detection of vulnerabilities and misconfigurations and maps those to the incidents, and automated incident coverage. It finally gives teams the operational evidence regulators require and the autonomy distributed AI environments demand.”

For organizations navigating a complex regulatory landscape, the new Automated Compliance Center provides the essential visibility and evidence required for NIS2 and CRA readiness. It delivers real-time mapping, compliance proof, and automated reporting aligned with both frameworks.

“We built this architecture to cut through the noise of traditional security reporting,” said Oleg Mygryn, CTO of AI EdgeLabs. “By integrating custom OS verification with SBOM-based vulnerability detection, we give security teams a granular, prioritized view of their risk. Whether it’s a Linux misconfiguration or a firmware issue on a critical GPU node, our AI engine identifies the context and criticality, allowing teams to address the assets that matter most before they can be exploited.”

With Linux Audit and Compliance Center, AI EdgeLabs is extending its AI-native protection deeper into the runtime layer, giving organizations the continuous compliance visibility required by emerging regulations.

About AI EdgeLabs

AI EdgeLabs is an AI-native, autonomous runtime protection platform for regulated AI workloads, GPU clusters, edge, hybrid cloud, and sovereign environments. Built to secure regulated AI workloads and infrastructure in real-time, AI EdgeLabs delivers threat detection and response capabilities where CNAPPs can’t reach, ensuring the integrity of distributed infrastructure across the globe.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260113487666/en/

Contacts

Inna Ushakova, CEO
+19733235639
iu@edgelabs.ai
https://edgelabs.ai -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fedgelabs.ai&es
heet=54386807&newsitemid=20260113487666&lan=en-US&anchor=https%3A%2F%2Fedgelabs.
ai&index=4&md5=aee6c107d1ffc581bf549cabc940dddf
https://www.linkedin.com/company/ai-edgelabs/ -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.c
om%2Fcompany%2Fai-edgelabs%2F&esheet=54386807&newsitemid=20260113487666&lan=en-U
S&anchor=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fai-edgelabs%2F&index=5&md5=8
0ef1eb0fa50cdc98185ae72fed45f23

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye